Zhou Na, Chen Chengchuan, Liu Yubei, Yu Zhaolan, Bello Aminu K, Chen Yanhua, Liu Ping
School of Nursing, Southwest Medical University, Luzhou, Sichuan Province, China.
Department of Cardiology, The First Affiliated Hospital, Chengdu Medical College, Chengdu, Sichuan Province, China.
PLoS One. 2024 Dec 10;19(12):e0309973. doi: 10.1371/journal.pone.0309973. eCollection 2024.
Assessing the quality of chronic kidney disease (CKD) management is crucial for optimal care and identifying care gaps. It is largely unknown which quality indicators have been widely used and the potential variations in the quality of CKD care. We sought to summarize process quality indicators for CKD and assess the quality of CKD care.
We searched databases including Medline (Ovid), PubMed, Cochrane Library, Web of Science, CINAHL, and Scopus from inception to June 20, 2024. Two reviewers screened the identified records, extracted relevant data, and classified categories and themes of quality indicators.
We included 24 studies, extracted 30 quality indicators, and classified them into three categories with nine themes. The three categories included laboratory measures and monitoring of CKD progression and/or complications (monitoring of kidney markers, CKD mineral and bone disorder, anemia and malnutrition, electrolytes, and volume), use of guideline-recommended therapeutic agents (use of medications), and attainment of therapeutic targets (blood pressure, glycemia, and lipids). Among the frequently reported quality indicators (in five or more studies), the following have a median proportion of study participants achieving that quality indicator exceeding 50%: monitoring of kidney markers (Scr/eGFR), use of medications (ACEIs/ARBs, avoiding non-steroidal anti-inflammatory drugs (NSAIDs)), management of blood pressure (with a target of ≤140/90, or without specific targets), and monitoring for glycated hemoglobin A1c (HbA1c)). The presence of diabetes, hypertension, cardiovascular disease, or proteinuria was associated with higher achievement in indicators of monitoring of kidney markers, use of recommended medications, and management of blood pressure and glycemia.
The quality of CKD management varies with quality indicators. A more consistent and complete reporting of key quality indicators is needed for future studies assessing CKD care quality.
评估慢性肾脏病(CKD)管理质量对于实现最佳治疗和识别护理差距至关重要。目前尚不清楚哪些质量指标被广泛使用以及CKD护理质量的潜在差异。我们旨在总结CKD的过程质量指标并评估CKD护理质量。
我们检索了包括Medline(Ovid)、PubMed、Cochrane图书馆、科学网、CINAHL和Scopus在内的数据库,检索时间从建库至2024年6月20日。两名评审员筛选了检索到的记录,提取相关数据,并对质量指标的类别和主题进行分类。
我们纳入了24项研究,提取了30个质量指标,并将它们分为三类九个主题。这三类包括实验室指标以及对CKD进展和/或并发症的监测(肾脏标志物监测、CKD矿物质和骨异常、贫血和营养不良、电解质及容量)、指南推荐治疗药物的使用(药物使用)以及治疗目标的达成情况(血压、血糖和血脂)。在经常报告的质量指标中(五项或更多研究),以下指标的研究参与者达到该质量指标的中位数比例超过50%:肾脏标志物监测(Scr/eGFR)、药物使用(ACEI/ARB,避免使用非甾体抗炎药(NSAIDs))、血压管理(目标≤140/90,或无特定目标)以及糖化血红蛋白A1c(HbA1c)监测。糖尿病、高血压、心血管疾病或蛋白尿的存在与肾脏标志物监测、推荐药物使用以及血压和血糖管理指标的更高达成率相关。
CKD管理质量因质量指标而异。未来评估CKD护理质量的研究需要更一致和完整地报告关键质量指标。